eptinezumab


( Last Updated : November 17, 2022)
Generic Name:
eptinezumab
Project Status:
Active
Therapeutic Area:
Migraine
Manufacturer:
Lundbeck Canada Inc.
Call for patient/clinician input open:
Brand Name:
Vyepti
Project Line:
Reimbursement Review
Project Number:
SR0743-000
Call for patient/clinician input closed:
NOC Status at Filing:
Post NOC

Details


Manufacturer Requested Reimbursement Criteria1:
For the prevention of migraine in adults who have at least four migraine days per month and have experienced an inadequate response, intolerance, or contraindication to at least two oral prophylactic migraine medications.
Submission Type:
Initial
Fee Schedule:
Schedule A
Indications:
For the prevention of migraine in adults who have at least 4 migraine days per month.
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.

Key Milestones2

Call for patient/clinician input open11-May-22
Call for patient/clinician input closed04-Jul-22
Clarification:

- Patient input submission received from Migraine Canada & Migraine Quebec

Submission received08-Jun-22
Submission accepted22-Jun-22
Review initiated23-Jun-22
Draft CADTH review report(s) provided to sponsor for comment08-Sep-22
Deadline for sponsors comments19-Sep-22
CADTH review report(s) and responses to comments provided to sponsor14-Oct-22
Expert committee meeting (initial)26-Oct-22
Draft recommendation issued to sponsor08-Nov-22
Draft recommendation posted for stakeholder feedback17-Nov-22
End of feedback period01-Dec-22